Tofacitinib

  • Brand Name - Xeljanz
  • API - Tofacitinib Citrate
  • Packaging - 60 Tablets
  • Strength - 5 mg
  • Manufacturer Name - Pfizer Labs

WHAT IS TOFACITINIB AND WHAT IT IS USED FOR:

Tofacitinib  is a Janus kinase (JAK) inhibitor indicated for the treatment of:

Rheumatoid Arthritis:  in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other non biologic disease-modifying antirheumatic drugs (DMARDs). 

Psoriatic Arthritis: in adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). 

Ulcerative Colitis: in adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or who are intolerant to TNF blockers.

GET PRICE
Tofacitinib Dosage

Tofacitinib should be taken orally at about the same time each day, either with or without food. Tofacitinib tablets should be swallowed whole with water. The tablets should not be opened, broken, or Chewed.

Tofacitinib side effects

Rheumatoid and Psoriatic Arthritis: Most common side effects of tofacitinib include upper respiratory tract infection, nasopharyngitis, diarrhea, and headache.

Ulcerative Colitis: Most common adverse reactions include nasopharyngitis, elevated cholesterol levels, headache, upper respiratory tract infection, increased blood creatine phosphokinase, rash, diarrhea, and herpes zoster.

Warnings and Precautions
  • Use of this medication in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
  • Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Xeljanz 5 mg.
  • Caution is also recommended in patients with a history of chronic lung disease, or in those who develop interstitial lung disease, as they may be more prone to infections.
  • Risk of infection could be greater with an increasing degree of the lymphopenia and consideration must be given to lymphocyte counts when assessing individual patient risk of infection. Interruption and monitoring criteria for the lymphopenia must be recommended.
  • Consultation with a healthcare professional or physician with the expertise in the treatment of tuberculosis must be recommended in order to aid in the decision about whether starting anti-tuberculosis therapy is appropriate for an individual patient.
  • Patients should be closely  and precisely monitored for the development of symptoms of tuberculosis, including patients who found negative for the latent tuberculosis infection before initiating therapy.
  • Non-melanoma skin cancers (NMSCs) have been reported in patients treated with XELJANZ 5MG. Skin examination should be recommended periodically for patients who are at increased risk for skin cancer.
  • Avoid Xeljanz Rheumatoid Arthritis drug in patients that may be at increased risk of thrombosis.
  • Tofacitinib 5 mg must be used with a lot of caution in patients who are at increased risk for gastrointestinal perforation.
  • Patients presenting with the new onset abdominal signs should be observed promptly for early identification of the gastrointestinal perforation.
  • Hypersensitivity has been observed in patients receiving XELJANZ 5MG TABLET. In case if a serious hypersensitivity reaction appears, promptly discontinue or interrupt this drug while evaluating the potential causes of reactions.
  • Patients with psoriatic arthritis treatment should be monitored for lymphocyte counts at baseline and every 3 months thereafter. Recommended modifications should be based on the lymphocyte counts.
  • Routine monitoring of liver tests should be recommended and prompt investigation of the causes of the liver enzyme elevations is also recommended in order to identify the potential cases of drug-induced liver injury.
Supplied/Storage and handling

Care should be exercised in the handling of AFANAT. AFANAT tablets should not be opened or crushed. Store permitted between 15-30°C (59-86°F).  Keep this medication in the original container and keep the container tightly closed also away from the moisture and light.

Drug interaction of Tofacitinib
  • Tofacitinib exposure is enhanced when co-administered with potent inhibitors of CYP3A4 (e.g., ketoconazole) or when the use of one or more concomitant drugs results in moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole).
  • Tofacitinib exposure is reduced when co-administered with potent CYP3A4 inducers (e.g., rifampicin). Inhibitors of CYP2C19 alone or P-glycoprotein are unlikely to significantly alter the PK (pharmacokinetics) of tofacitinib.
  • Co-administration of ketoconazole, a strong CYP3A4 inhibitor, with a single dose of tofacitinib enhanced the AUC and Cmax of tofacitinib by 103 & 16 percent, respectively.
  • Co-administration of fluconazole, a moderate inhibitor of CYP3A4 and a strong inhibitor of CYP2C19, enhanced the AUC and Cmax of tofacitinib by 79 and 27 percent, respectively.
  • Co-administration of cyclosporin, a moderate inhibitor of CYP3A4, enhanced the AUC of tofacitinib by 73 percent and reduced Cmax of tofacitinib by 17 percent. Combined administration of multiple-dose tofacitinib with this potent immunosuppressive has not been assessed in patients with RA or PsA and is contraindicated.
  • Co-administration of tacrolimus, a mild inhibitor of CYP3A4, reduced the AUC of tofacitinib by 21 percent and reduced the Cmax of tofacitinib by 9 percent. The combined use of multiple-dose tofacitinib with this potent immunosuppressive has not been assessed in patients with RA or PsA and is not recommended.
  • Co-administration of rifampicin, a strong CYP3A4 inducer, reduced the AUC and Cmax of tofacitinib by 84 & 74 percent, respectively.

Commonly asked questions:

Tofacitinib citrate is the active ingredient.

The inactive ingredients are croscarmellose sodium, HPMC 2910/Hypromellose 6cP, lactose monohydrate, macrogol/PEG3350, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin.

Yes, treatment with XELJANZ is associated with an increased incidence of neutropenia.

The medication should be avoided to use in pregnant women.

In case of an overdose of Tofacitinilb, consult the doctor immediately and keep the patient under observation for any signs and symptoms. There is no antidote for the medicine.

  • Tofacitinib cost is low if you go with generic brand, you can buy it from any authorized whole seller after getting prescription from a qualified doctor. It is always better to check the credential of the whole seller/supplier/exporter before buying the product.
  • The buyer should check the existing law in their home country before importing the product.

Patients can simply fill the order form or can send mail at info@ikrispharmanetwork.com. Patient can also send WhatsApp message to +91 8130290915. We will reply ASAP with the details of Pricing and procedure.
Note:- The order will be confirmed only after the receipt of Valid prescription of Clinician

Store the medicine at a temperature between 15-30°C (59-86°F).
Keep this medication in the original container and keep the container tightly closed, also away from moisture and light.

Disclaimer

All Trademark and Brand that appear on the website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. Tofacitinib is a pharmaceutical drug that legally requires a medical prescription to be dispensed.

Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller and Pharmacies.